Intec Pharma Granted Patent in Hong Kong for Accordion Pill Carbidopa, Levodopa

JERUSALEM: Intec Pharma Ltd., a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill^[TM] platform technology, announces that the Patent Registry Intellectual Property Department of Hong Kong has issued a Certificate of Grant of a Hong Kong patent for an Accordion Pill containing certain drugs, including the combination of Carbidopa and Levodopa.

The patent, granted under No. HK1158545, is titled "Carbidopa/Levodopa Gastroretentive Drug Delivery" and is currently scheduled to remain in force until April 2029. The patent belongs to the Company's IN-7 patent family, which already includes patents granted in the U.S., Europe, China, Japan, South Korea, South Africa and Israel.

"We remain committed to building out our IN-7 patent family in order to fortify our global leadership in gastric retention drug delivery with the Accordion Pill technology platform and this patent further strengthens that position," stated Jeffrey A. Meckler, Chief Executive Officer of Intec Pharma.

"This Hong Kong patent secures key elements of our Accordion Pill technology platform and our leading product, the Accordion Pill Carbidopa/Levodopa (AP-CD/LD), in significant markets. The AP-CD/LD is currently in a global Phase III clinical trial in advanced Parkinson's disease and the expanded patent protection will enhance any global commercial efforts for AP-CDLD."